48,936 Shares in Gilead Sciences, Inc. $GILD Purchased by Te Ahumairangi Investment Management Ltd

Te Ahumairangi Investment Management Ltd bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, Holdings Channel reports. The firm bought 48,936 shares of the biopharmaceutical company’s stock, valued at approximately $6,183,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of GILD. Persistent Asset Partners Ltd acquired a new stake in Gilead Sciences in the second quarter valued at $25,000. Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences during the 4th quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC grew its holdings in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares during the last quarter. Quattro Advisors LLC purchased a new position in Gilead Sciences during the fourth quarter worth $26,000. Finally, Wealth Preservation Advisors LLC raised its holdings in shares of Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the transaction, the chief executive officer directly owned 592,133 shares of the company’s stock, valued at approximately $77,160,851.23. The trade was a 2.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the transaction, the insider owned 118,234 shares in the company, valued at $16,273,727.76. This represents a 19.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 87,000 shares of company stock worth $11,562,960. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $146.12 on Monday. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29. The stock has a market cap of $181.18 billion, a price-to-earnings ratio of -54.73 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The company has a fifty day moving average price of $131.97 and a 200 day moving average price of $136.55.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter in the previous year, the firm posted $2.01 earnings per share. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences, Inc. will post -0.51 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on GILD shares. Daiwa Securities Group dropped their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. Rothschild & Co Redburn decreased their price target on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Morgan Stanley cut their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research report on Monday, July 27th. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Wednesday, May 20th. Finally, Weiss Ratings lowered Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $158.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.